1. Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients
- Author
-
Eduardo Cervantes-Alvarez, Nathaly Limon-de la Rosa, Moises Salgado-de la Mora, Paola Valdez-Sandoval, Mildred Palacios-Jimenez, Fatima Rodriguez-Alvarez, Brenda I. Vera-Maldonado, Eduardo Aguirre-Aguilar, Juan Manuel Escobar-Valderrama, Jorge Alanis-Mendizabal, Osvely Méndez-Guerrero, Farid Tejeda-Dominguez, Jiram Torres-Ruíz, Diana Gómez-Martín, Kathryn L. Colborn, David Kershenobich, Christene A. Huang, and Nalu Navarro-Alvarez
- Subjects
Medicine ,Science - Abstract
Abstract Severe COVID-19 is associated with a systemic hyperinflammatory response leading to acute respiratory distress syndrome (ARDS), multi-organ failure, and death. Galectin-3 is a ß-galactoside binding lectin known to drive neutrophil infiltration and the release of pro-inflammatory cytokines contributing to airway inflammation. Thus, we aimed to investigate the potential of galectin-3 as a biomarker of severe COVID-19 outcomes. We prospectively included 156 patients with RT-PCR confirmed COVID-19. A severe outcome was defined as the requirement of invasive mechanical ventilation (IMV) and/or in-hospital death. A non-severe outcome was defined as discharge without IMV requirement. We used receiver operating characteristic (ROC) and multivariable logistic regression analysis to determine the prognostic ability of serum galectin-3 for a severe outcome. Galectin-3 levels discriminated well between severe and non-severe outcomes and correlated with markers of COVID-19 severity, (CRP, NLR, D-dimer, and neutrophil count). Using a forward-stepwise logistic regression analysis we identified galectin-3 [odds ratio (OR) 3.68 (95% CI 1.47–9.20), p 50%, had significantly improved ability to predict severe outcomes [AUC 0.85 (95% CI 0.79–0.91, p
- Published
- 2022
- Full Text
- View/download PDF